ABIONYX Pharma announces its financial calendar for the year 2024
07 Março 2024 - 3:44PM
Business Wire
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies based on the world’s only
natural recombinant apoA-I, today announces its financial calendar
for 2024.
Events
Dates*
2023 Full-Year Results
Monday, March 11, 2024
Cash position and activity update for
Q1 2024
Thursday, May 16, 2024
Cash position and activity update for
Q2 2024
Thursday, August 22, 2024
2024 Half-Year Results
Thursday, September 26, 2024
Cash position and activity update for
Q3 2024
Thursday, November 14, 2024
* indicative dates subject to
change
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines in diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated apoA-I
-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240307659062/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53 NewCap
Media relations Arthur Rouillé abionyx@newcap.eu +33 (0)1 44 71 00
15
Abionyx Pharma (EU:ABNX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Abionyx Pharma (EU:ABNX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
